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Background/Introduction
As a consequence of limited donor availability, there has
been a growing interest for alternative strategies, such as
left ventricular assist devices (LVAD) as either a bridge
to transplantation (BTT) or as destination therapy (DT)
for the treatment of the advanced heart failure. The
heart transplant program in Kazakhstan is in a nascent
stage and therefore patients that are determined to be
BTT are expected to have an extended duration of
LVAD support.
Aims/Objectives
The objective of this study was to determine outcomes
of patients with left ventricular assist devices in country
with restricted transplantation.
Method
We analyzed outcomes for 135 patients between Novem-
ber 2011 and November 2014 (mean age=50,5 ± 13,5
years old; Heart Mate II = 95 (70,4%), HeartWare = 40
(29,6%)). The median duration of support is 474 ± 329,4
days.
Results
In 75 patients (55,6%) the LVAD is used as a BTT and in
60 (44,4%) as a DT, but only 3 of 135 LVAD patients
were transplanted. Before 30 days after implantation of
LVAD right ventricular failure (n = 20, 14,8%), renal fail-
ure (n = 19, 14,1%) and bleeding (requiring reoperation =
10, 7,4%, requiring transfusion of packed red blood cells
≥4U = 23, 17,04%) were the most common adverse
events. After 30 days driveline infections (n = 46, 34,1%)
and strokes (n = 33, 24,44%) were the most common
complications. Cumulative survival rates at 1, 6 months,
1, 2 and 3 years after LVAD implantation is 93%, 86%,
77%, 62% and 51% accordingly. Older age and more
acute INTERMACS profiles were related to reduced
survival.
Discussion/Conclusion
The Center’s experience shows that LVADs can be
implanted as an alternative to heart transplantation with
the outcomes that are comparable to those in existing
world centers of excellence.
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